|
시장보고서
상품코드
2082543
디지털 치료제 시장 : 제품 유형별, 치료 영역별, 플랫폼별, 채널 유형별, 최종 사용자별, 도입 형태별 시장 예측(2026-2032년)Digital Therapeutics Market by Product Type, Therapy Area, Platform, Channel Type, End User, Deployment Mode - Global Forecast 2026-2032 |
||||||
360iResearch
디지털 치료제 시장은 2032년까지 연평균 복합 성장률(CAGR) 15.92%로 성장이 전망되며, 180억 5,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 64억 1,000만 달러 |
| 추정 연도 : 2026년 | 73억 7,000만 달러 |
| 예측 연도 : 2032년 | 180억 5,000만 달러 |
| CAGR(%) | 15.92% |
디지털 치료제(DTx)란, 질환의 예방, 관리 또는 치료를 목적으로 설계된 근거 기반 소프트웨어 중재로, 대부분의 경우 단독으로 또는 의약품, 의료기기, 의료진의 치료와 병행하여 사용됩니다. 이 분야는 웰니스 관련 앱에서 무작위 대조 임상시험, 실세계 데이터, 사이버 보안 대책, 상호운용성 기준, 그리고 보험 급여 제도에 기반을 둔 규제 대상 의료용 소프트웨어로 점차 전환되고 있습니다.
만성 질환의 유병률, 행동 보건 분야의 인력 부족, 고령화, 그리고 병원이나 진료소 이외의 장소에서 제공되는 돌봄 서비스 확대의 필요성 등 의료 시스템에 장기적으로 가해지는 압박으로 인해 수요는 더욱 증가하고 있습니다. 의료기기로서의 소프트웨어에 대한 FDA의 감독, 독일의 DiGA 제도, 영국의 DTAC 프레임워크, 프랑스의 디지털 의료기기를 위한 조기 접근 제도 ‘PECAN’, 그리고 미국의 원격 치료 모니터링 관련 규정 등, 확인된 정책 동향은 디지털 테라퓨틱스가 커넥티드 케어 인프라의 공식적인 일부로 자리 잡고 있음을 보여줍니다.
디지털 치료제 분야의 혁신적인 변화
디지털 치료제의 현황은 소비자 대상의 실험 단계에서 의료 제공업체, 보험사, 고용주, 제약 업계의 이해관계자, 공중보건 시스템에 의한 기업 차원의 도입으로 전환되고 있습니다. 구매자들은 솔루션을 일반 대중에게 확대 적용하기 전에, 임상적 타당성, 의료경제학적 근거, 워크플로우와의 통합, 사용성 테스트, 데이터 보안 및 측정 가능한 성과를 점점 더 요구하고 있습니다.
디지털 치료제에 대한 인공지능의 누적 영향
인공지능(AI)은 적응형 개입, 맞춤형 코칭, 위험도 계층화, 자연어 기반 참여 유도, 그리고 진료팀에 대한 자동 에스컬레이션을 가능하게 함으로써 디지털 테라퓨틱스의 가치를 높이고 있습니다. AI는 환자의 행동, 동반 질환, 사회적 위험 요인 및 반응 패턴에 맞추어 개입의 강도를 조정하는 데 도움이 되며, 진료 간격 기간 동안 치료의 적절성을 높일 수 있습니다.
디지털 치료제 도입에 관한 주요 지역별 인사이트
북미는 선진적인 디지털 헬스 인프라, 보험사 주도의 실증 실험, 처방전 대상 디지털 치료제에 대한 FDA의 선례, 그리고 만성 질환 및 행동 건강 문제에 대한 확장 가능한 솔루션에 대한 고용주 수요 덕분에 디지털 치료제의 상용화 분야에서 계속해서 선도적인 지역으로 자리매김하고 있습니다. 미국은 원격 치료 모니터링에 대한 보험 청구 코드와 가치 기반 의료의 도입에 힘입어 상용화의 주요 원동력이 되고 있습니다. 한편, 캐나다는 공중보건의 디지털화 진전, 각 주에서 추진하는 가상 진료 사업, 그리고 만성 질환 관리에 대한 관심 고조로 인해 혜택을 보고 있습니다.
아세안(ASEAN), GCC, EU, 브릭스(BRICS), G7, 나토(NATO)의 주요 그룹별 인사이트
아세안 시장은 싱가포르, 인도네시아, 말레이시아, 태국, 베트남, 필리핀에서 스마트폰 보급률, 도시 지역의 의료 수요, 민관 주도의 디지털 헬스 이니셔티브가 증가하고 있어, 모바일 우선형 디지털 치료제에게 매력적인 시장으로 부상하고 있습니다. 특히, 당뇨병, 심혈관 및 대사 질환, 정신 건강, 호흡기 관리, 복약 순응도를 지원하는 솔루션은 현지 보험 급여 제도, 언어, 임상 업무 흐름, 데이터 보관 요건에 부합하는 지역에서 도입이 가장 활발히 이루어지고 있습니다.
디지털 치료제의 성장에 관한 주요 국가의 인사이트
미국은 소프트웨어 기반 의료 개입에 대한 FDA 인증 승인 절차, 원격 치료 모니터링을 위한 CPT 코드, 확립된 디지털 헬스 조달 채널, 그리고 성과 기반 치료에 대한 고용주와 보험사의 관심 덕분에 디지털 치료제(DTx)의 상용화를 주도하고 있습니다. 캐나다는 주 정부 체계와 전국적인 디지털 헬스 연계를 통해 가상 진료 및 만성 질환 관리를 추진하고 있습니다. 한편, 멕시코와 브라질은 방대한 인구, 만성 질환에 대한 수요 증가, 그리고 확장 가능한 디지털 헬스케어 접근성에 대한 민간 부문 수요 증가가 특징입니다.
디지털 테라퓨틱스 업계 리더을 위한 실천적 제안
업계 리더는 당뇨병, 고혈압, 불면증, 약물 사용 장애, 근골격계 질환, 호흡기 질환, 비만, 심혈관 위험 관리, 행동 건강 등 디지털 치료제가 측정 가능한 성과를 입증할 수 있는 임상적으로 검증된 활용 사례를 우선시해야 합니다. 증거 기반 전략에서는 무작위 대조 시험, 실세계 데이터, 환자 보고 결과, 의료경제학, 복약 순응도 지표, 안전성 모니터링, 하위군 분석을 종합하여 보험 급여 및 조달을 뒷받침해야 합니다.
디지털 치료제 분석을 위한 조사 기법
견고한 디지털 테라퓨틱스 조사 방법론에서는 규제 문서, 동료 심사를 거친 임상 근거, 보험사 정책, 보험 청구 코드, 임상 실무 지침, 공중보건 데이터 세트, 조달 활동, 특허 출원, 제품 등록 정보 및 전문가 인터뷰를 다각적으로 대조해야 합니다. 시장 평가에 있어서는 범주 확대를 피하기 위해 웰니스 앱과 임상적으로 검증된 DTx, 의료기기로서의 소프트웨어, 원격 모니터링, 커넥티드 질환 관리, 그리고 디지털 케어 내비게이션 플랫폼을 명확히 구분해야 합니다.
결론 : 의료 분야의 핵심 성장 시장으로서의 디지털 테라퓨틱스
디지털 테라퓨틱스는 임상적으로 입증된 소프트웨어 중재를 통해 환자, 임상의, 보험사, 생명과학 분야의 이해관계자들을 연결하는 현대 의료 분야의 전략적 축으로 자리매김하고 있습니다. 이 시장의 다음 단계는 앱 다운로드 수보다는 증거, 환급, 통합, 사이버 보안, 규제 준수, 그리고 지속 가능한 건강 성과에 의해 정의될 것입니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 디지털 치료제 시장 : 제품 유형별
제8장 디지털 치료제 시장 : 치료 영역별
제9장 디지털 치료제 시장 : 플랫폼별
제10장 디지털 치료제 시장 : 채널 유형별
제11장 디지털 치료제 시장 : 최종 사용자별
제12장 디지털 치료제 시장 : 도입 모드별
제13장 디지털 치료제 시장 : 지역별
제14장 디지털 치료제 시장 : 그룹별
제15장 디지털 치료제 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
AJY 26.07.15The Digital Therapeutics Market is projected to grow by USD 18.05 billion at a CAGR of 15.92% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 6.41 billion |
| Estimated Year [2026] | USD 7.37 billion |
| Forecast Year [2032] | USD 18.05 billion |
| CAGR (%) | 15.92% |
Digital therapeutics (DTx) are evidence-based software interventions designed to prevent, manage, or treat disease, often used independently or alongside medication, devices, and clinician-led care. The category is moving from wellness-adjacent apps toward regulated medical software supported by randomized clinical trials, real-world evidence, cybersecurity controls, interoperability standards, and reimbursement pathways.
Demand is being reinforced by durable health system pressures: chronic disease prevalence, behavioral health shortages, aging populations, and the need to extend care beyond hospitals and clinics. Verified policy signals, including FDA oversight of software as a medical device, Germany's DiGA pathway, the U.K.'s DTAC framework, France's PECAN early access pathway for digital medical devices, and U.S. remote therapeutic monitoring codes, show that digital therapeutics are becoming a formal part of connected care infrastructure.
Transformative Shifts in the Digital Therapeutics Landscape
The digital therapeutics landscape is shifting from direct-to-consumer experimentation to enterprise adoption by providers, payers, employers, pharmaceutical stakeholders, and public health systems. Buyers increasingly require clinical validation, health economic evidence, workflow integration, usability testing, data security, and measurable outcomes before scaling solutions across populations.
A second shift is the convergence of DTx with telehealth, remote patient monitoring, electronic health records, pharmacy services, and value-based care contracts. This integration is changing the competitive benchmark: successful platforms must not only engage patients, but also deliver longitudinal data, clinician decision support, adherence insights, and compliance with privacy, accessibility, and medical device regulations.
Cumulative Impact of Artificial Intelligence on Digital Therapeutics
Artificial intelligence is amplifying the value of digital therapeutics by enabling adaptive interventions, personalized coaching, risk stratification, natural-language engagement, and automated escalation to care teams. AI can help match intervention intensity to patient behavior, comorbidities, social risk factors, and response patterns, improving the relevance of therapy between clinical visits.
The cumulative impact is also increasing regulatory and governance expectations. Industry leaders must validate AI models across diverse populations, monitor algorithm drift, document clinical safety, protect health data, and maintain explainability where outputs affect treatment. Responsible AI is becoming a competitive differentiator as payers, providers, and regulators demand evidence that digital therapeutics are safe, equitable, clinically meaningful, and auditable over time.
Key Regional Insights for Digital Therapeutics Adoption
North America remains a leading region for digital therapeutics commercialization due to advanced digital health infrastructure, payer experimentation, FDA precedent for prescription digital therapeutics, and employer demand for scalable chronic and behavioral health solutions. The United States is the primary commercialization engine, supported by remote therapeutic monitoring reimbursement codes and value-based care adoption, while Canada benefits from strong public health digitization, provincial virtual care initiatives, and growing attention to chronic disease management.
Europe is shaped by structured assessment and reimbursement models, particularly Germany's DiGA program, France's digital medical device reimbursement initiatives, the U.K.'s DTAC assessment framework, and broader EU emphasis on GDPR, medical device regulation, interoperability, and evidence-based software. Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia invest in telehealth, mobile-first care, digital hospitals, and aging-population management. Latin America shows rising demand in diabetes, cardiovascular risk, mental health, and access-to-care use cases, with Brazil and Mexico acting as important adoption centers. The Middle East is accelerating through national digital health strategies in Gulf markets, where prevention, chronic care, and smart hospital programs are policy priorities. Africa remains earlier-stage but strategically important, with mobile health adoption, primary care access gaps, expanding broadband initiatives, and donor-supported digital health infrastructure creating long-term DTx opportunities.
Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO
ASEAN markets are attractive for mobile-first digital therapeutics because smartphone penetration, urban healthcare demand, and public-private digital health initiatives are increasing across Singapore, Indonesia, Malaysia, Thailand, Vietnam, and the Philippines. Adoption is strongest where solutions support diabetes, cardiometabolic disease, mental health, respiratory care, and medication adherence while fitting local reimbursement, language, clinical workflow, and data residency requirements.
The European Union is advancing a rules-based DTx environment through GDPR, medical device regulation, health data space initiatives, cross-border interoperability priorities, and national reimbursement experiments. GCC countries are investing in digital health as part of economic diversification, preventive care strategies, and health system modernization, creating favorable conditions for digitally enabled chronic disease and behavioral health programs. BRICS markets represent scale, chronic disease burden, and cost-sensitive innovation potential, although regulatory heterogeneity, reimbursement fragmentation, and access disparities remain significant. G7 markets provide the deepest evidence, reimbursement, procurement, and clinical integration opportunities, while NATO countries overlap substantially with high-income digital health systems prioritizing cybersecurity, resilience, continuity of care, and trusted health data exchange.
Key Country Insights for Digital Therapeutics Growth
The United States leads in DTx commercialization, supported by FDA-recognized pathways for software-based medical interventions, CPT codes for remote therapeutic monitoring, established digital health procurement channels, and employer and payer interest in outcomes-based care. Canada is advancing virtual care and chronic disease management through provincial systems and national digital health collaboration, while Mexico and Brazil offer large populations, rising chronic disease needs, and growing private-sector demand for scalable digital health access.
In Europe, the United Kingdom's NHS assessment frameworks, Germany's DiGA reimbursement pathway, and France's digital medical device reimbursement initiatives make these markets influential for evidence standards and procurement expectations. Italy and Spain are strengthening telehealth, electronic health records, and chronic care modernization, while Russia remains complex due to geopolitical, reimbursement, and procurement constraints. In Asia-Pacific, China offers scale and policy-driven digital health expansion, India provides mobile-first demand and substantial chronic disease needs, Japan prioritizes aging-related care, regulated quality, and clinical safety, Australia supports remote care across dispersed populations, and South Korea combines strong connectivity with advanced digital hospital ecosystems and government interest in smart healthcare.
Actionable Recommendations for Digital Therapeutics Leaders
Industry leaders should prioritize clinically validated use cases where digital therapeutics can demonstrate measurable outcomes, such as diabetes, hypertension, insomnia, substance use disorder, musculoskeletal care, respiratory disease, obesity, cardiovascular risk management, and behavioral health. Evidence strategies should combine randomized trials, real-world evidence, patient-reported outcomes, health economics, adherence metrics, safety monitoring, and subgroup analyses to support reimbursement and procurement.
Companies should also design for integration from the start. Interoperability with EHRs, remote monitoring devices, pharmacy systems, care management platforms, and clinician workflows improves adoption and reduces abandonment. Leaders should invest in privacy-by-design, cybersecurity, health equity testing, AI governance, accessibility, localization, and payer-aligned value propositions that translate engagement into reduced utilization, improved adherence, better quality measures, and sustained patient outcomes.
Research Methodology for Digital Therapeutics Analysis
A robust digital therapeutics research methodology should triangulate regulatory documents, peer-reviewed clinical evidence, payer policies, reimbursement codes, clinical practice guidelines, public health datasets, procurement activity, patent filings, product registries, and expert interviews. Market assessment should distinguish wellness apps from clinically validated DTx, software as a medical device, remote monitoring, connected disease management, and digital care navigation platforms to avoid category inflation.
The methodology should evaluate adoption by indication, care setting, business model, regulatory classification, evidence maturity, prescribing pathway, reimbursement readiness, and integration depth. Regional analysis should incorporate healthcare financing, data protection laws, physician adoption, smartphone access, digital literacy, language localization, procurement models, and health system priorities. AI-related analysis should review validation protocols, bias mitigation, post-market surveillance, model governance, explainability, algorithm change control, and clinical safety documentation.
Conclusion: Digital Therapeutics as a Core Healthcare Growth Market
Digital therapeutics are becoming a strategic layer of modern healthcare, connecting patients, clinicians, payers, and life sciences stakeholders through clinically guided software interventions. The market's next phase will be defined less by app downloads and more by evidence, reimbursement, integration, cybersecurity, regulatory alignment, and sustained health outcomes.
Organizations that combine medical rigor with user-centered design, responsible AI, secure data practices, interoperability, and scalable partnerships will be best positioned to lead. As healthcare systems seek accessible, cost-effective, and personalized care models, digital therapeutics are set to play an expanding role in chronic disease management, behavioral health, preventive care, and digitally enabled population health.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Digital Therapeutics Market, by Product Type
- 7.1. Non-Prescription / Over-the-Counter (OTC) Digital Therapeutics
- 7.2. Prescription Digital Therapeutics (PDTx)
8. Digital Therapeutics Market, by Therapy Area
- 8.1. Diabetes Management
- 8.2. Neurological Disorders
- 8.2.1. Depression
- 8.2.2. Anxiety Disorders
- 8.2.3. Schizophrenia
- 8.2.4. Epilepsy
- 8.2.5. Multiple Sclerosis
- 8.3. Obesity & Weight Management
- 8.4. Chronic Respiratory Diseases
- 8.5. Cardiovascular Diseases
- 8.6. Mental & Behavioral Health
- 8.7. Musculoskeletal Disorders / Pain Management
- 8.8. Oncology Support Care
- 8.9. Gastrointestinal Disorders
- 8.10. Smoking Cessation
- 8.11. Women's Health
- 8.12. Rehabilitation & Physical Therapy
- 8.13. Substance Use Disorders
- 8.14. Sleep Disorders
9. Digital Therapeutics Market, by Platform
- 9.1. Smartphone-Based Applications
- 9.2. Wearable Device-Integrated DTx
- 9.3. AI/ML-Based Digital Therapies
- 9.4. Virtual Reality (VR)-Based DTx
- 9.5. Digital Monitoring + Feedback Systems
- 9.6. Web-Based / Cross-Platform Therapeutics
10. Digital Therapeutics Market, by Channel Type
- 10.1. Patients / Direct-to-Consumer (D2C)
- 10.2. Healthcare Providers (Hospitals & Clinics)
- 10.3. Employers / Corporate Wellness Programs
- 10.4. Pharmaceutical Partnerships
- 10.5. Government & Public Health Systems
11. Digital Therapeutics Market, by End User
- 11.1. Patients
- 11.2. Healthcare Providers
- 11.3. Employers & Corporate Wellness
- 11.4. Caregivers & Rehabilitation Centers
12. Digital Therapeutics Market, by Deployment Mode
- 12.1. Cloud-Based
- 12.2. On-Premise
- 12.3. Hybrid Deployment
13. Digital Therapeutics Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Digital Therapeutics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Digital Therapeutics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. 2morrow Inc.
- 17.2. Abbott Laboratories
- 17.3. AptarGroup, Inc.
- 17.4. Big Health, Inc.
- 17.5. Biofourmis Inc.
- 17.6. Canary Health Technologies Inc.
- 17.7. Click Therapeutics, Inc.
- 17.8. CogniFit Inc.
- 17.9. Cognoa, Inc.
- 17.10. CureApp, Inc.
- 17.11. DarioHealth Corp.
- 17.12. F. Hoffmann-La Roche Ltd
- 17.13. Fitterfly Healthtech Private Limited by PB Healthcare Services Pvt. Ltd.
- 17.14. GAIA AG
- 17.15. Glooko, Inc.
- 17.16. Grunenthal GmbH
- 17.17. H2O Therapeutics Co.
- 17.18. Headspace Inc.
- 17.19. Hinge Health, Inc.
- 17.20. Hyfe, Inc.
- 17.21. Kaia Health Software Inc.
- 17.22. Lark Technologies, Inc.
- 17.23. LifeScan, Inc.
- 17.24. Lumanity Inc.
- 17.25. Lumos Labs
- 17.26. MedRhythms
- 17.27. Noom, Inc.
- 17.28. Novartis AG
- 17.29. Novo Nordisk A/S
- 17.30. Omada Health, Inc.
- 17.31. Otsuka Holdings Co., Ltd.
- 17.32. ResMed, Inc.
- 17.33. SilverCloud by American Well Corporation
- 17.34. Teladoc Health, Inc.
- 17.35. Teva Pharmaceutical Industries Ltd.
- 17.36. Vida Health, Inc.
- 17.37. Virtual Therapeutics Corp.
- 17.38. Welldoc, Inc.
